Results
with
DUPIXENT
BROOKE,
Actual DUPIXENT patient.
Individual results may vary.
Actual DUPIXENT patient.
Individual results may vary.
results you can
see and feel
Backed by science, DUPIXENT is the first FDA-approved treatment for adults with prurigo nodularis (PN).
CLINICAL TRIAL RESULTS
In two clinical studies with 311 adults with PN:
At 24 Weeks
59%
HAD NOTICEABLY
LESS ITCH
LESS ITCH
59% on DUPIXENT vs 19% not on DUPIXENT
At 24 Weeks
46%
SAW SKIN CLEAR OR ALMOST
CLEAR OF PN BUMPS
CLEAR OF PN BUMPS
46% on DUPIXENT vs 17% not on DUPIXENT
At 24 Weeks
46%
SAW SKIN CLEAR OR ALMOST
CLEAR OF PN BUMPS
CLEAR OF PN BUMPS
46% on DUPIXENT vs 17% not on DUPIXENT
At 24 Weeks
59%
HAD NOTICEABLY
LESS ITCH
LESS ITCH
59% on DUPIXENT vs 19% not on DUPIXENT
IN ONE STUDY
In As Little As 12 Weeks
37%
EXPERIENCED
LESS ITCH
LESS ITCH
37% on DUPIXENT vs 22% not on DUPIXENT
VIEW SAFETY RESULTS
MOST COMMON SIDE EFFECTS IN PATIENTS WITH PRURIGO NODULARIS INCLUDE:
- Eye and eyelid inflammation, including redness,
swelling, and itching, sometimes with blurred vision - Herpes virus infections
- Common cold symptoms (nasopharyngitis)
- Dizziness
- Muscle pain
- Diarrhea
View Before and After Results With DUPIXENT
Results with 32 weeks of treatment with DUPIXENT
Click and drag
to see results
to see results
Click and drag
to see results
to see results
Actual patient shown. Additional factors, including possible use of other treatments, may have impacted results. Individual results may vary.
A Helpful Reminder
Get valuable info from this video to help you during your treatment journey.
Prepare For Your Doctor Appointment
You have a lot of questions and deserve to get the right answers. Our personalized discussion guide lets you document PN symptoms and severity so you can have a more productive conversation with your doctor.